A phase II study of DuP 937 (Teloxantrone) in metastatic malignant melanoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCICCTG).
Shore
T
T
Manitoba Cancer Treatment and Research Foundation, Winnipeg, Canada.
Eisenhauer
E
E
Quirt
I
I
Belanger
K
K
Lohmann
R
R
Silver
H
H
Wielgosz
G
G
D000880:Anthraquinones / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002170:Canada; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis; D011720:Pyrazoles / Q000627:therapeutic use*
D000880:Anthraquinones; D000970:Antineoplastic Agents; D011720:Pyrazoles; C046658:teloxantrone